POLE and colorectal carcinoma: Finally, in the randomized POLEM trial, the addition of avelumab to standard adjuvant fluoropyrimidine-based chemotherapy will be assessed in stage III resected dMMR/MSI-H or POLE-mutant CRC patients [60].